Priority review clock is ticking as Incyte’s zilurgisertib posts striking FOP lesion data

Incyte’s investigational FOP drug zilurgisertib has delivered dramatic reductions in new bone lesion volume and now sits under FDA priority review, putting a rare-disease niche product squarely on biotech investors’ radar.

Edited by ad hoc news New Releases & Launches Desk. Reviewed before publication on 06/15/2026 at 11:46 PM ET. Details in the imprint.

Zilurgisertib, the investigational fibrodysplasia ossificans progressiva (FOP) therapy co-developed by Mirum Pharmaceuticals and Incyte, has moved into the biotech spotlight after pivotal Phase 2 data showed an almost complete suppression of new abnormal bone lesion volume over 24 weeks and continued benefit through 48 weeks, while the drug’s US filing now sits under FDA Priority Review with a September 26, 2026 target decision date. According to the companies’ joint June 14 press release, patients on zilurgisertib in the PROGRESS Phase 2 study saw an 81% reduction in the proportion developing new heterotopic ossification (HO) lesions versus placebo and a 99.9% reduction in the total volume of those new lesions at Week 24. For a disease where even minor trauma can trigger irreversible bone formation in muscles and soft tissue, these numbers are unusual enough to reset expectations around what a targeted oral therapy might deliver.

What zilurgisertib is designed to do in FOP – and what the new data show

FOP is an ultra-rare genetic disorder driven by activating mutations in ACVR1 (also known as ALK2) that cause the body to gradually replace muscle and connective tissue with bone, severely limiting mobility and leading to life-threatening complications; prevalence is often estimated in the low thousands worldwide, leaving patients with almost no approved options and a pressing need for disease-modifying treatment. Zilurgisertib is an oral small-molecule ALK2 inhibitor developed to interrupt that aberrant signaling and thereby reduce the formation of heterotopic bone, with Mirum leading the FOP program and Incyte contributing its kinase development expertise and infrastructure. The pivotal Phase 2 PROGRESS study evaluated zilurgisertib in patients 12 years and older with FOP, comparing the drug with placebo over 24 weeks followed by an open-label extension to Week 48, using whole-body low-dose CT to quantify new and existing HO lesions alongside clinical measures such as flare activity.

In Cohort 1 of PROGRESS, only one patient on zilurgisertib developed a new HO lesion by Week 24 compared with five patients in the placebo group, translating into the 81% reduction in the proportion of patients with new lesions highlighted by the companies, while total new lesion volume on drug was almost completely suppressed relative to placebo, with the reported 99.9% reduction in volume through Week 24. At the same time, patients receiving zilurgisertib experienced a net reduction in the total volume of existing HO lesions, whereas those on placebo showed an increase over the same period, pointing not only to prevention of new abnormal bone but also to a shift in the underlying lesion burden. These radiographic findings line up with clinical observations: the companies report that flare activity, a key driver of new bone formation in FOP, was lower in the zilurgisertib arm during the 24-week placebo-controlled phase and remained low during the extension period, indicating that the biological effect translated into fewer acute disease exacerbations for patients.

The extension data to Week 48 have become a crucial part of the story. Among patients who started on zilurgisertib from baseline, no new HO lesions were observed between Weeks 24 and 48, and the total HO lesion volume continued to decline, suggesting durability of effect beyond the initial placebo-controlled window. In the cohort that began on placebo and crossed over to zilurgisertib at Week 24, no new lesions were detected during the subsequent 24 weeks, and their lesion volume also decreased, implying that the therapy can exert a consistent effect even when initiated later in the disease course. Investigators and the companies describe the safety profile as generally favorable, with most treatment-related adverse events mild to moderate, low rates of serious events in both arms, no discontinuations or dose reductions attributed to adverse events, and a side-effect pattern dominated by manageable complaints such as nausea, which is in line with prior early-stage experience and important given the chronic nature of treatment.

Regulators have taken note. The US Food and Drug Administration has accepted the New Drug Application for zilurgisertib for the treatment of FOP in patients aged 12 and older and has granted Priority Review status, shortening the standard review timeline and underscoring the perceived unmet medical need and potential clinical impact of the data package submitted. The agency has set a Prescription Drug User Fee Act action date of September 26, 2026, effectively starting the clock on whether zilurgisertib could become one of the first broadly accessible targeted oral therapies for FOP in the US; given the complexity of the disease and the limited competition, market observers are now working through how a potential approval would translate into pricing, patient identification strategies and real-world evidence demands. Outside the US, Mirum and Incyte are expected to use the Phase 2 dataset to support discussions with other regulators, but timelines for ex-US filings have not been detailed publicly, and reimbursement pathways will likely differ sharply between major markets.

From the perspective of Incyte’s broader portfolio, zilurgisertib sits in a growing set of late-stage programs that extend the company’s footprint beyond its established hematology and oncology products such as Jakafi (ruxolitinib) and the anti-CD19 antibody tafasitamab (marketed as Monjuvi/Minjuvi in collaboration with MorphoSys), which recently delivered positive Phase 3 frontMIND data in high-risk diffuse large B-cell lymphoma when combined with lenalidomide and R-CHOP. As reported by Clinical Trials Arena on the frontMIND results, Incyte has been systematically pushing combinations and targeted agents to deepen its presence in defined patient segments, and the company’s pipeline updates at major hematology meetings in 2025 and 2026 have repeatedly featured new small-molecule and antibody programs. Against that backdrop, zilurgisertib is strategically relevant less for sheer revenue potential, which will be constrained by the ultra-rare nature of FOP, and more for what it signals about Incyte’s willingness to invest in high-science, high-barrier orphan indications that can support premium pricing, scientific prestige and long patent tails, all of which matter for a mid-cap biotech balancing mature cash-cow assets with future growth stories.

For equity investors tracking the name, the zilurgisertib update is one of several catalysts in a packed 2026 calendar, but the stock’s near-term behavior continues to be driven primarily by expectations around core franchises and the broader sentiment toward mid-cap biotech. MarketBeat data show Incyte’s shares (ticker: INCY) trading on the Nasdaq in the low-$100 range in recent sessions, with modest year-to-date gains and a cluster of updated analyst price targets following recent clinical news. Shares of Incyte (ISIN US45337C1027) traded on Nasdaq at around $102 in mid-June 2026, illustrating how the market is currently treating pipeline wins like zilurgisertib’s FOP data as incremental supports to an already diversified product base rather than wholesale reratings on single-asset risk.

Zilurgisertib for FOP in brief: key product facts

• Product: Zilurgisertib
• Manufacturer: Incyte Corporation / Mirum Pharmaceuticals Inc.
• Category: New Release / Rare-disease therapy candidate
• Launch date: Not yet marketed; US FDA PDUFA target action date September 26, 2026
• MSRP / Price: Not yet disclosed; pricing will depend on regulatory approvals and payer negotiations
• Availability: Currently limited to clinical trials such as the Phase 2 PROGRESS study; no commercial availability as of mid-2026
• Target audience: Patients 12 years and older living with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disease that causes abnormal bone formation in muscles and soft tissues
• Key differentiator / USP: Oral ALK2 inhibitor that has shown an 81% reduction in the proportion of patients developing new HO lesions and a 99.9% reduction in total new lesion volume versus placebo at 24 weeks, with continued suppression of new lesions and decreasing lesion volume through 48 weeks in clinical testing

This article was a.i.-assisted and editorially reviewed. Product information without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Trading involves risk up to and including the total loss of invested capital.